Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

نویسندگان

  • Jozef Bartunek
  • Andre Terzic
  • Beth A. Davison
  • Gerasimos S. Filippatos
  • Slavica Radovanovic
  • Branko Beleslin
  • Bela Merkely
  • Piotr Musialek
  • Wojciech Wojakowski
  • Peter Andreka
  • Ivan G. Horvath
  • Amos Katz
  • Dariouch Dolatabadi
  • Badih El Nakadi
  • Aleksandra Arandjelovic
  • Istvan Edes
  • Petar M. Seferovic
  • Slobodan Obradovic
  • Marc Vanderheyden
  • Nikola Jagic
  • Ivo Petrov
  • Shaul Atar
  • Majdi Halabi
  • Valeri L. Gelev
  • Michael K. Shochat
  • Jaroslaw D. Kasprzak
  • Ricardo Sanz-Ruiz
  • Guy R. Heyndrickx
  • Noémi Nyolczas
  • Victor Legrand
  • Antoine Guédès
  • Alex Heyse
  • Tiziano Moccetti
  • Francisco Fernandez-Aviles
  • Pilar Jimenez-Quevedo
  • Antoni Bayes-Genis
  • Jose Maria Hernandez-Garcia
  • Flavio Ribichini
  • Marcin Gruchala
  • Scott A. Waldman
  • John R. Teerlink
  • Bernard J. Gersh
  • Thomas J. Povsic
  • Timothy D. Henry
  • Marco Metra
  • Roger J. Hajjar
  • Michal Tendera
  • Atta Behfar
  • Bertrand Alexandre
  • Aymeric Seron
  • Wendy Gattis Stough
  • Warren Sherman
  • Gad Cotter
  • William Wijns
چکیده

Aims Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. Methods and results This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein-Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann-Whitney estimator 0.54, 95% confidence interval [CI] 0.47-0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients) (Mann-Whitney estimator 0.61, 95% CI 0.52-0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. Conclusion The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design

AIMS Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomi...

متن کامل

Aloe vera Leaf Gel in Treatment of Advanced Type 2 Diabetes Mellitus Needing Insulin Therapy: A Randomized Double-Blind Placebo-Controlled Clinical Trial

 Background: Advanced type 2 diabetes mellitus (T2DM) needing insulin therapy is a common disease. Previous studies indicate that aloe (Aloe vera L.) leaf gel may positively affect the blood glucose and lipid levels in patients with advanced T2DM needing insulin.  Objective: Evaluation of the efficacy and safety of aloe leaf gel in the treatment of type 2 diabetic patients resistant to ...

متن کامل

Letter to editor: the critical appraisal of “efficacy of licorice extract in the treatment of melasma: a randomized, double-blind, lacebo-controlled clinical trial”

This is a letter to editor criticizing the paper entitled “Efficacy of licorice extract in the treatment of melasma: A randomized, double-blind, placebo-controlled clinical trial”. We discuss some methodological points on external and internal validity of results. The paper suffers from lack of detailed information on sample size and power calculation to make sure generalisability of results to...

متن کامل

The efficacy of oral Erythromycin in the treatment of patients with Pityriasis Rosea: A randomized double-blind, placebo-controlled clinical trial

Background: Pityriasis rosea is an acute, inflammatory and self-limited disease, which is characterized by a primary scaly plaque (Herald patch) followed by a generalized, symmetrical papulosqumous eruption (Mostly on trunk and proximal extremities). Objective: To determine the efficacy of erythromycin in the treatment of patients with pityriasis rosea. Patients and Methods: In this doubl...

متن کامل

Maintenance Therapy by Vaginal Progesterone after Threatened Idiopathic Preterm Labor: A Randomized Placebo-Controlled Double-blind Trial

Background Patients with arrested preterm labor (PTL) are at increased risk for recurrence of preterm birth (PTB). Maintenance tocolysis after arrest of acute PTL is of questionable value. The objective of this study was to evaluate the efficacy of 200 mg vaginal progesterone in order to prevent PTB in women with episodes of threatened PTL. MaterialsAndMethods This is a randomized double blind ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 38  شماره 

صفحات  -

تاریخ انتشار 2017